On this webpage COVID-19 vaccine resources for pharmacists are provided.
Maintained by: Timothy P. Gauthier, Pharm.D., BCPS, BCIDP, Bassam Ghanem, Pharm.D., MS, BCPS, and Jeanette Bouchard, Pharm.D.
First Published: 28 December 2020
Last updated: 31 May 2021 – We are no longer updating this webpage.
On this webpage we are listing links to COVID-19 vaccine resources for pharmacists. You will find general information, links to vaccine-specific content, and links to vaccine literature. Sections include:
- Clinical FAQs & Guidelines
- Education
- Playbooks & Toolkits
- Resource Webpages
- People on Twitter Worth Watching
- COVID-19 Vaccine Use Trackers
- Specific Vaccines
- Moderna (mRNA-1273)
- Pfizer-BioNTech (BNT162b2)
- Johnson & Johnson/Janssen (Ad26.CoV2.S)
- Oxford/ Astrazenica (AZD1222)
- Gam-COVID-Vac (Sputnik V)
- Clover Biopharmaceuticals (SCB-2019)
- Novavax (NVX-CoV2373)
- CoronaVac
- Bharat BioNTech (BBV152)
- COVID-19 Vaccine Literature
- COVID-19 Vaccine News Articles / Press Releases
- Other notes
Have a resource that is not listed yet? Let us know here.
Clinical FAQs & Guidelines
- CDC Interim Clinical Considerations for Use of mRNA COVID-19 Vaccines Currently Authorized in the United States
- CDC webpage on COVID-19 Vaccines and Severe Allergic Reactions
- ACIP COVID-19 Vaccination Recommendations
- World Health Organization – Draft landscape of COVID-19 candidate vaccines
- NEJM – Covid-19 Vaccine — Frequently Asked Questions
- Immunize.IO COVID Vaccine FAQ
- FDA EUA for Vaccines Explained
- Development and Licensure of Vaccines to Prevent COVID-19
Education
- Coronavirus Vaccine Update From the CDC With Nancy E. Messonnier, MD – JAMA
- CDC Clinician Outreach and Communication (COCA) Calls/Webinars
- Includes recorded webinars, PDF handouts, and sign up option for email alerts
- Evaluating and Caring for Patients with Post-COVID Conditions
- Underlying Medical Conditions and Severe COVID-19: Evidence-based Information for Healthcare Providers
- What Clinicians Need to Know About Pfizer-BioNTech COVID-19 Vaccination of Adolescents
- Johnson & Johnson/Janssen COVID-19 Vaccine and Thrombosis with Thrombocytopenia Syndrome (TTS): Update for Clinicians
- Johnson & Johnson/Janssen COVID-19 Vaccine and Cerebral Venous Sinus Thrombosis with Thrombocytopenia – Update for Clinicians on Early Detection and Treatment
- What Every Clinician Should Know about COVID-19 Vaccine Safety and Effectiveness and How to Address Patient Questions and Concerns
- What Clinicians Need to Know About Johnson & Johnson’s Janssen COVID-19 Vaccine
- COVID-19 Vaccines: Update on Allergic Reactions, Contraindications, and Precautions
- What Clinicians Need to Know About the Pfizer-BioNTech and Moderna COVID-19 Vaccines
- What Every Clinician Should Know about COVID-19 Vaccine Safety
- Includes recorded webinars, PDF handouts, and sign up option for email alerts
- CDC COVID-19 Webinar and Partner Calls Videos
- Society of Infectious Diseases Pharmacists Videos
Playbooks & Toolkits
- USP – COVID-19 Vaccine Handling Toolkit: Operational Considerations for Healthcare Practitioners
- CEP Vaccine Tools Page
- Development of Monoclonal Antibody Products Targeting SARS-CoV-2, Including Addressing the Impact of Emerging Variants, During the COVID 19 Public Health Emergency
Resource Webpages
- CDC COVID-19 Vaccines Webpage
- WHO lists additional COVID-19 vaccine for emergency use and issues interim policy recommendations
- HHS Public Health Emergency Website
- IDSA COVID-19 Vaccine Website
On Twitter Worth Watching
Blog Articles
- Are We Expecting Too Much from Our COVID-19 Vaccines? – NEJM Blog
- How many people have to be immunised to provide herd immunity? – Peter English
COVID-19 Vaccine Use Trackers
- Johns Hopkins Vaccines Tracker
- Our world in Data Coronavirus (COVID-19) Vaccinations
- New York Times Coronavirus Vaccine Tracker (extensive information provided)
Moderna COVID-19 Vaccine (mRNA-1273)
- Moderna COVID-19 Vaccine Webpage
- Includes Fact Sheet for Healthcare Providers and Fact Sheet for Patients
- Moderna Vaccine Expiration Lookup
- CDC Moderna COVID-19 Vaccine Webpage
- CDC Moderna COVID-19 Vaccine Preparation & Administration Summary
- Moderna FDA Briefing Document
- Moderna FDA EUA Letter
- WHO – Interim recommendations for use of the Moderna mRNA-1273 vaccine against COVID-19
- Literature:
- Immediate reactions following the first dose of the SARS-CoV2 mRNA vaccines do not preclude second dose administration – CID
- Delayed Localized Hypersensitivity Reactions to the Moderna COVID-19 Vaccine A Case Series – JAMA Dermatology
- Administration of a Second Dose of the Moderna COVID-19 Vaccine After an Immediate Hypersensitivity Reaction With the First Dose: Two Case Reports – Annals of IM
- Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19
- Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2
- mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants (Pre-print)
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
- Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases
- Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021
- Other:
- Moderna Announces TeenCOVE Study of its COVID-19 Vaccine in Adolescents Meets Primary Endpoint and Plans to Submit Data to Regulators in Early June
- Moderna Announces Positive Initial Booster Data Against SARS-CoV-2 Variants of Concern
- Coronavirus (COVID-19) Update: FDA Makes Two Revisions to Moderna COVID-19 Vaccine Emergency Use Authorization to Help Increase the Number of Vaccine Doses Available
PFIZER-BioNTech COVID-19 Vaccine (BNT162b2)
- Pfizer/BioNTech COVID-19 Vaccine Webpage
- Pfizer COVID-19 Resources
- BioNTech COVID-19 Resources
- Pfizer-BioNTech COVID-19 Vaccine Fact Sheet for Recipients
- Pfizer-BioNTech COVID-19 Vaccine Fact Sheet for Healthcare Providers
- Pfizer-BioNTech FDA Briefing Document
- Pfizer COVID-19 Vaccine Webpage
- CDC Pfizer-BioNTech Vaccine Webpage
- CDC Pfizer-BioNTech Vaccine Preparation & Administration Summary
- WHO – Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing
- ASHP – COVID-19 Vaccine Security, Storage, and Handling Resource Guide
- Literature:
- BNT162b2 mRNA vaccination did not prevent an outbreak of SARS COV-2 variant 501Y.V2 in an elderly nursing home but reduced transmission and disease severity – CID
- Association of Facial Paralysis With mRNA COVID-19 VaccinesA Disproportionality Analysis Using the World Health Organization Pharmacovigilance Database -JAMA
- SARS-CoV-2 infection of BNT162b2(mRNA)-vaccinated individuals is not restricted to variants of concern or high-risk exposure environments – Pre-Print
- BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants – NEJM
- The effectiveness of the TWO-DOSE BNT162b2 vaccine: analysis of real-world data – CID
Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine – Nature Medicine - Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors – Lancet Oncology
- Herpes zoster following BNT162b2 mRNA Covid-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series – Rheumatology
- Neutralizing Activity of BNT162b2-Elicited Serum – NEJM
- BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting – NEJM
- Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera
- Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine – JAMA
- Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine — United States, December 14–23, 2020
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
- Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021
- Other information
- Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021
- FDA In Brief: FDA Authorizes Longer Time for Refrigerator Storage of Thawed Pfizer-BioNTech COVID-19 Vaccine Prior to Dilution, Making Vaccine More Widely Available
PFIZER-BIONTECH ANNOUNCE POSITIVE TOPLINE RESULTS OF PIVOTAL COVID-19 VACCINE STUDY IN ADOLESCENTS - PFIZER AND BIONTECH CONFIRM HIGH EFFICACY AND NO SERIOUS SAFETY CONCERNS THROUGH UP TO SIX MONTHS FOLLOWING SECOND DOSE IN UPDATED TOPLINE ANALYSIS OF LANDMARK COVID-19 VACCINE STUDY
- Coronavirus (COVID-19) Update: FDA Allows More Flexible Storage, Transportation Conditions for Pfizer-BioNTech COVID-19 Vaccine
- Pfizer and Biontech initiate a study as part of broad development plan to evaluate COVID-19 booster and new vaccine variants
- EU brand name: Comirnaty
- Coined from COVID-19 community, immunity& embeds mRNA in the middle
- Pronounced phonetically as koe mir’ na tee
- International generic name: Tozinameran
- Tozina- is the invented prefix required by the World Health Organization
- -meran is the required suffix for new mRNA Vaccines.
- Pronounced as toe zi na’ mer an
Johnson & Johnson/Janssen COVID-19 Vaccine (Ad26.CoV2.S)
- Janssen COVID-19 Webpage
- Janssen COVID Vaccine – Fact Sheet for Recipients
- Janssen COVID Vaccine – Fact Sheet for Healthcare Providers
- Janssen COVID Vaccine – FDA Advisory Meeting & Briefing Document
- Janssen COVID Vaccine – FDA EUA Letter
- Janssen COVID Vaccine – FDA EUA Announcement
- Joint CDC and FDA Statement on Johnson & Johnson COVID-19 Vaccine
- FDA and CDC Lift Recommended Pause on Johnson & Johnson (Janssen) COVID-19 Vaccine Use Following Thorough Safety Review
- The Johnson & Johnson Vaccine for COVID-19 – JAMA Patient Page
- Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine
- Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial
Oxford/ AstraZenica COVID-19 Vaccine (ChAdOx1 nCoV-19 [AZD-1222])
- Vaccines and Related Biological Products Advisory Committee February 26, 2021 – Briefing Documents
- Fatal cerebral venous sinus thrombosis after COVID-19 vaccination – Intensive Care Medicine
- Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination – NEJM
- Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial – LANCET
- Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant – NEJM
- Safety and efficacy of the ChAdOx1 nCoV-19 (AZD1222) Covid-19 vaccine against the B.1.351 variant in South Africa – PREPRINT
- Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine
- UK Government AstraZenica COVID-19 Vaccine Resources
- Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
- AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19
- AZD1222 US Phase III primary analysis confirms safety and efficacy
Gam-COVID-Vac (Sputnik V)
Clover Biopharmaceuticals COVID-19 Vaccine (SCB-2019)
CoronaVac
- Effectiveness of the CoronaVac vaccine in the elderly population during a P.1 variant-associated epidemic of COVID-19 in Brazil: A test-negative case-control study – Pre-Print
- Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial – LANCET ID
Novavax COVID-19 Vaccine (NVX-CoV2373)
- Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant – NEJM
- Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial
Bharat Biotech COVID-19 Vaccine (BBV152)
COVID-19 Vaccine Literature
Newest additions are towards the top, oldest additions are towards the bottom
- Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data – LANCET
- SARS-CoV-2 escaped natural immunity, raising questions about vaccines and therapies – Nature
- Preliminary Analysis of Association Between COVID-19 Vaccination and Sudden Hearing Loss Using US Centers for Disease Control and Prevention Vaccine Adverse Events Reporting System Data – JAMA
- Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in AdultsA Randomized Clinical Trial – JAMA
- SARS-CoV-2 Vaccine–Induced Immune Thrombotic Thrombocytopenia – NEJM
- Reactogenicity Following Receipt of mRNA-Based COVID-19 Vaccines – JAMA
- COVID-19 Vaccine: Practical Clinical Considerations – Annals IM
- mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection – Science
- Evaluating the Long-Term Efficacy of COVID-19 Vaccines – CID
- Acute Allergic Reactions to mRNA COVID-19 Vaccines – JAMA
- SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines – Cell and Host Microbe
- Are some COVID vaccines better than others? Interpreting and comparing estimates of efficacy in trials of COVID-19 vaccines – CID
- Bell’s palsy and SARS-CoV-2 vaccines – LANCET ID
- SARS-CoV-2 Vaccines – JAMA
- Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US—December 14, 2020-January 18, 2021
- Navigating the Quagmire: Comparison and Interpretation of COVID-19 Vaccine Phase 1/2 Clinical Trials – Vaccines
- Inactivated COVID-19 vaccines to make a global impact – LANCET ID
- The impact of vaccination on COVID-19 outbreaks in the United States
- Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine — United States, December 21, 2020–January 10, 2021 – CDC MMWR
- Covid-19: People who have had infection might only need one dose of mRNA vaccine
- The case against delaying SARS-CoV-2 mRNA vaccine boosting doses
- The impact of vaccination on COVID-19 outbreaks in the United States
- Accelerate COVID-19 Vaccine Rollout by Delaying the Second Dose of mRNA Vaccines
- SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement
- Key areas for further research are discussed, including vaccine hesitancy and its effect in the IBD community, the effect of immunosuppression on vaccine efficacy, and the search for predictive biomarkers of vaccine success.
- Looking beyond COVID-19 vaccine phase 3 trials – Nature Medicine
- Vaccinology in the post−COVID-19 era
- mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions: Current Evidence and Approach
- This review summarizes vaccine allergy epidemiology and proposes risk stratification schema: (1) for individuals with different allergy histories to safely receive their first COVID-19 vaccine and (2) for individuals who develop a reaction to their first dose of COVID-19 vaccine.
- Maintaining Safety with SARS-CoV-2 Vaccines
- Viral targets for vaccines against COVID-19
- Designing the Next Generation of Vaccines: Relevance for Future Pandemics
- A guide to vaccinology: from basic principles to new developments
- Reinfection with SARS-CoV-2: Implications for Vaccines
- Evaluating the Efficacy of COVID-19 Vaccines
- ASHP outlines tenets for COVID-19 vaccination rollout
- The VACCINES Act: Deciphering Vaccine Hesitancy in the Time of COVID-19
- Poses the question: what will the vaccine hesitant do in the face of this pandemic?
- Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
- ChAdOx1 nCoV-19 showed an acceptable safety profile, and homologous boosting increased antibody responses.
- Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial
- The Ad5-vectored COVID-19 vaccine at 5 × 1010 viral particles is safe, and induced significant immune responses in the majority of recipients after a single immunisation.
- Encouraging results from phase 1/2 COVID-19 vaccine trials (Commentary)
COVID-19 Vaccine News Articles / Press Releases
- Covid-19: Where are we on vaccines and variants? – BMJ News
- SARS-CoV-2 Vaccines – JAMA
- Oxford University extends COVID-19 vaccine study to children
- World’s first coronavirus Human Challenge study receives ethics approval in the UK
- WHO lists two additional COVID-19 vaccines for emergency use and COVAX roll-out
- The AstraZeneca vaccine may slow transmission of the virus
- EMA recommends COVID-19 Vaccine AstraZeneca for authorisation in the EU
- Merck Discontinues Development of SARS-CoV-2/COVID-19 Vaccine Candidates; Continues Development of Two Investigational Therapeutic Candidates
- Peak antibodies support Australia’s COVID-19 vaccine strategy
- Covid-19: Norway investigates 23 deaths in frail elderly patients after vaccination
- FDA Statement on Following the Authorized Dosing Schedules for COVID-19 Vaccines
- Extra dose from vials of Comirnaty COVID-19 vaccine
- China approves Sinopharm Covid-19 vaccine for general use
- Oxford University/AstraZeneca vaccine authorised by UK medicines regulator
- AstraZeneca’s COVID-19 vaccine authorised for emergency supply in the UK
- AstraZeneca Covid-19 vaccine study put on hold due to suspected adverse reaction in participant in the U.K.
Other Notes
- List-serves from societies such as ASHP, IDSA, and the ACCP ID PRN can serve as valuable resources for practical questions. Memberships required.
Have a resource that is not listed yet? Let us know here.
RECOMMENDED TO YOU
